Literature DB >> 14697785

2,6-Bis(3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays.

Roberta Costi1, Roberto Di Santo, Marino Artico, Silvio Massa, Rino Ragno, Roberta Loddo, Massimiliano La Colla, Enzo Tramontano, Paolo La Colla, Alessandra Pani.   

Abstract

A number of 2,6-bisbenzylidenecyclohexane-1-one derivatives have been synthesized and tested as HIV-1 integrase (IN) inhibitors with the aim of obtaining compounds capable to elicit antiviral activity at non-cytotoxic concentrations in cell-based assays. 3,5-Bis(3,4,5-trihydroxybenzylidene)-4-oxocyclohexaneacetic acid (20d) resulted one of the most potent and selective derivatives in acutely infected MT-4 cells (EC(50) and CC(50) values of 2 and 40 microM, respectively). In enzyme assays with recombinant HIV-1 integrase (rIN), this compound proved able to inhibit both 3'-processing and disintegration with IC(50) values of 0.2 and 0.5 microM, respectively. In order to develop a model capable to predict the anti HIV-IN activity and useful to design novel derivatives, we performed a comparative molecular field analysis (CoMFA) like 3-D-QSAR. In our model the ligands were described quantitatively in the GRID program, and the model was optimized by selecting only the most informative variables in the GOLPE program. We found the predictive ability of the model to increase significantly when the number of variables was reduced from 20,925 to 1327. A Q(2) of 0.73 was obtained with the final model, confirming the predictive ability of the model. By studying the PLS coefficients in informative 3-D contour plots, ideas for the synthesis of new compounds could be generated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14697785     DOI: 10.1016/j.bmc.2003.10.005

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  12 in total

1.  6-(1-Benzyl-1H-pyrrol-2-yl)-2,4-dioxo-5-hexenoic acids as dual inhibitors of recombinant HIV-1 integrase and ribonuclease H, synthesized by a parallel synthesis approach.

Authors:  Roberta Costi; Mathieu Métifiot; Francesca Esposito; Giuliana Cuzzucoli Crucitti; Luca Pescatori; Antonella Messore; Luigi Scipione; Silvano Tortorella; Luca Zinzula; Ettore Novellino; Yves Pommier; Enzo Tramontano; Christophe Marchand; Roberto Di Santo
Journal:  J Med Chem       Date:  2013-11-05       Impact factor: 7.446

Review 2.  Computer tools in the discovery of HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

Review 3.  Therapeutic Properties of Bioactive Compounds from Different Honeybee Products.

Authors:  Laura Cornara; Marco Biagi; Jianbo Xiao; Bruno Burlando
Journal:  Front Pharmacol       Date:  2017-06-28       Impact factor: 5.810

4.  Comparative docking and CoMFA analysis of curcumine derivatives as HIV-1 integrase inhibitors.

Authors:  Pawan Gupta; Prabha Garg; Nilanjan Roy
Journal:  Mol Divers       Date:  2011-02-15       Impact factor: 2.943

5.  CLEFMA-an anti-proliferative curcuminoid from structure-activity relationship studies on 3,5-bis(benzylidene)-4-piperidones.

Authors:  Pallavi Lagisetty; Prachi Vilekar; Kaustuv Sahoo; Shrikant Anant; Vibhudutta Awasthi
Journal:  Bioorg Med Chem       Date:  2010-06-22       Impact factor: 3.641

6.  Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action.

Authors:  Roberto Di Santo; Roberta Costi; Alessandra Roux; Marino Artico; Antonio Lavecchia; Luciana Marinelli; Ettore Novellino; Lucia Palmisano; Mauro Andreotti; Roberta Amici; Clementina Maria Galluzzo; Lucia Nencioni; Anna Teresa Palamara; Yves Pommier; Christophe Marchand
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

7.  Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines.

Authors:  Tiffany J Somers-Edgar; Sebastien Taurin; Lesley Larsen; Anupama Chandramouli; Mark A Nelson; Rhonda J Rosengren
Journal:  Invest New Drugs       Date:  2009-10-09       Impact factor: 3.850

Review 8.  Active site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase.

Authors:  Angela Corona; Takashi Masaoka; Graziella Tocco; Enzo Tramontano; Stuart F J Le Grice
Journal:  Future Med Chem       Date:  2013-12       Impact factor: 3.808

9.  Structure-guided approach identifies a novel class of HIV-1 ribonuclease H inhibitors: binding mode insights through magnesium complexation and site-directed mutagenesis studies.

Authors:  Vasanthanathan Poongavanam; Angela Corona; Casper Steinmann; Luigi Scipione; Nicole Grandi; Fabiana Pandolfi; Roberto Di Santo; Roberta Costi; Francesca Esposito; Enzo Tramontano; Jacob Kongsted
Journal:  Medchemcomm       Date:  2018-02-01       Impact factor: 3.597

10.  HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.

Authors:  Francesca Esposito; Angela Corona; Enzo Tramontano
Journal:  Mol Biol Int       Date:  2012-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.